Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Retained Earnings (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Retained Earnings for 6 consecutive years, with -$293.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 34.96% year-over-year to -$293.0 million, compared with a TTM value of -$293.0 million through Sep 2025, down 34.96%, and an annual FY2024 reading of -$237.7 million, down 34.59% over the prior year.
  • Retained Earnings was -$293.0 million for Q3 2025 at Barinthus Biotherapeutics, down from -$278.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$73.0 million in Q1 2021 and bottomed at -$293.0 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$159.6 million, with a median of -$145.2 million recorded in 2023.
  • The sharpest move saw Retained Earnings grew 12.22% in 2022, then crashed 94.14% in 2023.
  • Year by year, Retained Earnings stood at -$108.6 million in 2021, then increased by 4.92% to -$103.2 million in 2022, then tumbled by 71.04% to -$176.6 million in 2023, then plummeted by 34.59% to -$237.7 million in 2024, then fell by 23.28% to -$293.0 million in 2025.
  • Business Quant data shows Retained Earnings for BRNS at -$293.0 million in Q3 2025, -$278.4 million in Q2 2025, and -$257.3 million in Q1 2025.